Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020258 | 0.79 | TDP1 (0.81) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL343419 | 0.77 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL343629 | 0.77 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL140853 | 0.77 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL3025184 | 0.77 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5162656 | 0.77 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL137629 | 0.77 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL136815 | 0.77 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL134329 | 0.77 | TDP1 (0.85) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL14645239 | 0.77 | TDP1 (0.54) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149541-B2 | Tyrosine ligation process | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9149541-B2 | Tyrosine ligation process | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9149541-B2 | Tyrosine ligation process | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| EP-2729178-A1 | TYROSINE LIGATION PROCESS | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| CN-103764171-A | Tyrosine ligation process | NOVARTIS AG | 2014-04-30 | — | — | CN | disclosed |
| WO-2013009564-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | ACP1, LTK, TTL | TDP1 1088/4885MAOA 322/4885MAOB 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.